Ocugen reports promising interim results for OCU410 clinical trial in geographic atrophy
Ocugen, Inc. has taken a significant step forward in the fight against geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD), a leading cause ... Read More
Astellas Pharma to acquire avacincaptad pegol developer Iveric Bio for $6bn
Japanese pharma company Astellas Pharma has agreed to acquire Nasdaq-listed Iveric Bio in an all-cash deal worth around $5.9 billion with an aim to create ... Read More
Apellis to submit NDA for intravitreal pegcetacoplan to FDA in H1 2022
Apellis Pharmaceuticals said that it is on track to submit a new drug application (NDA) for its intravitreal pegcetacoplan to the US Food and Drug ... Read More
Janssen acquires HMR59 from Hemera for geographic atrophy treatment
Janssen Pharmaceuticals has secured the rights to an innovative gene therapy, HMR59, for the treatment of geographic atrophy, a severe form of age-related macular degeneration ... Read More